Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Call for Action: Benzodiazepine Prescription Prevalence Analysis Shows Off-Label Prescription in One in Eleven Citizens.

López-Pelayo H, Coma A, Gual A, Zara C, Lligoña A.

Eur Addict Res. 2019 Sep 6:1-10. doi: 10.1159/000502518. [Epub ahead of print]

PMID:
31494655
2.

ICD-11 for Alcohol Use Disorders: Not a Convincing Answer to the Challenges.

Rehm J, Heilig M, Gual A.

Alcohol Clin Exp Res. 2019 Aug 19. doi: 10.1111/acer.14182. [Epub ahead of print] No abstract available.

PMID:
31424579
3.

Cue-Elicited Anxiety and Alcohol Craving as Indicators of the Validity of ALCO-VR Software: A Virtual Reality Study.

Ghiţă A, Hernández-Serrano O, Fernández-Ruiz Y, Monras M, Ortega L, Mondon S, Teixidor L, Gual A, Porras-García B, Ferrer-García M, Gutiérrez-Maldonado J.

J Clin Med. 2019 Aug 2;8(8). pii: E1153. doi: 10.3390/jcm8081153.

4.

Motor Adaptation Impairment in Chronic Cannabis Users Assessed by a Visuomotor Rotation Task.

Herreros I, Miquel L, Blithikioti C, Nuño L, Rubio Ballester B, Grechuta K, Gual A, Balcells-Oliveró M, Verschure P.

J Clin Med. 2019 Jul 18;8(7). pii: E1049. doi: 10.3390/jcm8071049.

5.

Digital brief interventions for risky drinkers are not the panacea: A pilot study exploring barriers for its implementation according to professionals' perceptions.

López-Pelayo H, Caballeria E, Díaz E, Sánchez A, Segura L, Colom J, Wallace P, Gual A.

Health Informatics J. 2019 Jun 18:1460458219855177. doi: 10.1177/1460458219855177. [Epub ahead of print]

PMID:
31213133
6.

What Do Real Alcohol Outpatients Expect about Alcohol Transdermal Sensors?

Barrio P, Teixidor L, Andreu M, Gual A.

J Clin Med. 2019 Jun 5;8(6). pii: E795. doi: 10.3390/jcm8060795.

7.

Factors affecting engagement of primary health care professionals and their patients in facilitated access to online alcohol screening and brief intervention.

López-Pelayo H, Wallace P, Miquel L, Segura L, Baena B, Barrio P, Colom J, Gual A; EFAR group.

Int J Med Inform. 2019 Jul;127:95-101. doi: 10.1016/j.ijmedinf.2019.04.018. Epub 2019 Apr 24.

PMID:
31128838
8.

DSM-5 in patients seeking their first treatment for alcohol use disorder. Sex differences in the multicenter CohRTA study.

Sanvisens A, Zuluaga P, Rubio G, Short A, Gual A, Álvarez FJ, Torrens M, Rodríguez de Fonseca F, Muga Bustamante R, Estudio CohRTA EC.

Adicciones. 2019 Apr 8;0(0):1177. doi: 10.20882/adicciones.1177. [Epub ahead of print] English, Spanish.

9.

The relationship between motivations for cannabis consumption and problematic use.

Casajuana Kögel C, López-Pelayo H, Oliveras C, Colom J, Gual A, Balcells-Oliveró MM.

Adicciones. 2019 Apr 8;0(0):1221. doi: 10.20882/adicciones.1221. [Epub ahead of print] English, Spanish.

10.

The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial.

Barrio P, Roncero C, Ortega L, Guardia J, Yuguero L, Gual A.

J Clin Med. 2019 Apr 6;8(4). pii: E471. doi: 10.3390/jcm8040471.

11.

Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the High-Risk Alcoholism Relapse Score.

Lombardo-Quezada J, Colmenero J, López-Pelayo H, Gavotti C, Lopez A, Crespo G, Lopez E, Gual A, Lligoña A, Navasa M.

Liver Transpl. 2019 Aug;25(8):1142-1154. doi: 10.1002/lt.25460. Epub 2019 Jun 25.

PMID:
30920118
12.

Why Less Is Always More in the Treatment of Alcohol Use Disorders.

Nutt DJ, Gual A, Anderson P, Rehm J.

JAMA Psychiatry. 2019 Apr 1;76(4):359-360. doi: 10.1001/jamapsychiatry.2018.2807. No abstract available.

PMID:
30865234
13.

Cerebellar alterations in cannabis users: A systematic review.

Blithikioti C, Miquel L, Batalla A, Rubio B, Maffei G, Herreros I, Gual A, Verschure P, Balcells-Oliveró M.

Addict Biol. 2019 Feb 27. doi: 10.1111/adb.12714. [Epub ahead of print]

PMID:
30811097
14.

Identifying Triggers of Alcohol Craving to Develop Effective Virtual Environments for Cue Exposure Therapy.

Ghiţă A, Teixidor L, Monras M, Ortega L, Mondon S, Gual A, Paredes SM, Villares Urgell L, Porras-García B, Ferrer-García M, Gutiérrez-Maldonado J.

Front Psychol. 2019 Jan 29;10:74. doi: 10.3389/fpsyg.2019.00074. eCollection 2019.

15.

Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse.

López-Pelayo H, Miquel L, Altamirano J, Bataller R, Caballeria J, Ortega L, Lligoña A, Gual A.

J Psychosom Res. 2019 Jan;116:75-82. doi: 10.1016/j.jpsychores.2018.11.020. Epub 2018 Nov 28.

PMID:
30654998
16.

Risky Alcohol Use: The Impact on Health Service Use.

Miquel L, Manthey J, Rehm J, Vela E, Bustins M, Segura L, Vieta E, Colom J, Anderson P, Gual A.

Eur Addict Res. 2018;24(5):234-244. doi: 10.1159/000493884. Epub 2018 Oct 3.

PMID:
30282079
17.

New Alcohol Biomarkers. New challenges.

Barrio P, Wurst FM, Gual A.

Alcohol Alcohol. 2018 Nov 1;53(6):762-763. doi: 10.1093/alcalc/agy064. No abstract available.

PMID:
30204846
18.

Publisher Correction: Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 28;4(1):18. doi: 10.1038/s41572-018-0021-8.

PMID:
30154473
19.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

Bramness JG, Dom G, Gual A, Mann K, Wurst FM.

Eur Addict Res. 2018;24(4):201-205. doi: 10.1159/000492757. Epub 2018 Aug 22.

PMID:
30134238
20.

Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 16;4(1):16. doi: 10.1038/s41572-018-0014-7. Review. Erratum in: Nat Rev Dis Primers. 2018 Aug 28;4(1):18.

PMID:
30115921

Supplemental Content

Loading ...
Support Center